'Orphan drugs' with high price points are being tested as treatments for COVID-19. There's a better way to spur low-cost innovation for new drugs.
Academic rigor, journalistic flair
Articles on Drug development
Displaying 1 - 20 of 70 articles
Whether you are predicting the outcome of an election or studying how effective a new drug is, there will always be some uncertainty. A margin of error is how statisticians measure that uncertainty.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Understanding how cells grow under a variety of conditions is necessary for diagnosing disease and developing treatments in the future.
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
Scientists have developed and tested a new anti-clotting drug in mice that shows promise for treating heart attacks and stroke. It may also prove useful for COVID-19.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
Treatment nationalism is a threat to us all.
It usually takes 10 years for a new vaccine to complete clinical trials, but we've been promised a COVID-19 vaccine in 12 to 18 months. Even if such fast-tracked development is possible, is it wise?
Drug repurposing represents our only hope for the treatment of COVID-19 in the short term. But quick and rigorous trials need to be run to provide evidence these drugs work.
Half of all patients who died of COVID-19 in Wuhan had a secondary infection.
If the coronavirus is a lock, a drug to defeat it is a key that needs to fit just right.
Canada is investing millions to develop COVID-19 treatments, but there are no safeguards to ensure that those vaccines and medications will be affordable and accessible to the people who need them.
Scientists are pursuing several different avenues to develop a vaccine for the novel coronavirus, but the process could take years.
Bioinformatics can be applied to a range of problems, such as understanding the genome sequence of organisms or coming up with new drugs.
The aim is to discover, develop and facilitate delivery of anti-malarial medicines to help tackle the burden of malaria in endemic countries and support malaria eradication.
Destruction of rainforests through wildfires or deforestation may harm human health. As these forests disappear, we may be losing precious medicinal plants that hold treatments for various diseases.
The antibiotic crisis must be viewed through a different lens.
Box jellyfish stings are excruciating and occasionally deadly. We have identified a common, cheap drug that is already on the market and which could be a treatment candidate with further development.
Techniques from topology can help us understand DNA and improve drug development.
Top contributors
-
Prof. Institute for Molecular Bioscience, The University of Queensland
-
Professor of Neuroscience, Lancaster University
-
Associate Professor of History, University of Wollongong
-
Associate professor, UNSW
-
Biostatistician, The University of Melbourne
-
Senior Lecturer Biostatistics and Data Management, The University of Queensland
-
Associate Professor of Biostatistics, Murdoch Children's Research Institute
-
Lyn Gilbert is a Friend of The Conversation.
Clinical Professor in Medicine and Infectious Diseases, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Emeritus Professor of Medical Ethics, The University of Queensland
-
Associate professor, The University of Melbourne
-
Adjunct Fellow, School of Law & School of Medicine, Western Sydney University
-
Executive General Manager Commercialisation and Research Contracts, Baker Heart and Diabetes Institute
-
Senior Fellow at Research for Social Change, University of Wollongong
-
Distinguished Writer In Residence, Arthur Carter Journalism Institute, New York University
